

Janwillem Kocks

Research Articles

1. **Kocks JWH**, et al. Feasibility and applicability of the paper and electronic COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ) in primary care: a clinimetric study. *NPJ Prim Care Respir Med* 2017; 27(1): 20. [PubMed] [Full Text]
2. Flokstra-de Blok BM, **Kocks JWH**, et al. Development of an allergy management support system in primary care. *J Asthma Allergy* 2017; 10: 57-65. [PubMed] [Full Text]
3. Westerik JAM, **Kocks JWH**, et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. *Respir Res* 2017;18(1): 31. [PubMed] [Full Text]
4. Kamusheva M, **Kocks JWH**, et al. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. *J Med Econ* 2017; 20(5): 503-509. [PubMed] [Full Text]
5. Bathoorn E, **Kocks JW**, et al. Real-life data on antibiotic prescription and sputum culture diagnostics in acute exacerbations of COPD in primary care. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 285-290. [PubMed] [Full Text]
6. Smid DE, **Kocks JH**, et al. Redefining cut-points for high symptom burden of the Global Initiative for Chronic Obstructive Lung Disease classification in 18,577 patients with chronic obstructive pulmonary disease. *J Am Med Dir Assoc* 2017; 8(12): 1097.e11–1097.e24. [PubMed] [Full Text]
7. Ryan D, **Kocks JWH**, et al.; on behalf of the Respiratory Effectiveness Group. Use of electronic medical records and biomarkers to manage risk and resource efficiencies. *Eur Clin Respir J* 2017; 4(1): 1293386. [PubMed] [Full Text]
8. Price DB, **Kocks JWH**, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. *PLoS One* 2016; 11(9): e0162903. [PubMed] [Full Text]
9. Lisspers K, **Kocks J**, et al. Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG. *NPJ Prim Care Respir Med* 2016; 26: 16016. [PubMed] [Full Text]
10. van Boven JF, **Kocks J**, et al. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 2191-2201. [PubMed] [Full Text]
11. van Gemert F, **Kocks J**, et al. Socio-economic factors, gender and smoking as determinants of COPD in a low-income country of sub-Saharan Africa: FRESH AIR Uganda. *NPJ Prim Care Respir Med* 2016; 26: 16050. [PubMed] [Full Text]
12. Alma H, **Kocks J**, et al. Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference. *NPJ Prim Care Respir Med* 2016; 26: 16041. [PubMed] [Full Text]
13. Tsiligianni I, **Kocks J**, et al. Morning and night symptoms in primary care COPD patients: a cross-sectional and longitudinal study. An UNLOCK study from the IPCRG. *NPJ Prim Care Respir Med* 2016; 26: 16040. [PubMed] [Full Text]
14. Tsiligianni IG, **Kocks J**, et al. Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George's Respiratory Questionnaire cutoff 25 (and 20) as reference. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 1045-1052. [PubMed] [Full Text]
15. Metting EI, **Kocks JWH**, et al. Development of a diagnostic decision tree for obstructive pulmonary diseases based on real-life data. *ERJ Open Res* 2016;2(1). [PubMed] [Full Text]
16. Metting EI, **Kocks JWH**, et al. Asthma/COPD service in general practice. Study into feasibility and effectiveness. *Ned Tijdschr Geneesk* 2016; 160(0): D281. [PubMed] [Full Text]
17. Fattahi F, **Kocks JWH**, et al. Old dilemma: asthma with irreversible airway obstruction or COPD. *Virchows Arch* 2015; 467(5): 583-593. [PubMed] [Full Text]
18. Saleh-Langenberg J, **Kocks JWH**, et al. Epinephrine auto-injector prescriptions to food-allergic patients in primary care in The Netherlands. *Allergy Asthma Clin Immunol* 2015; 11: 28. [PubMed] [Full Text]
19. Hendriks SH, **Kocks JWH**, et al. Validation of the howRu and howRwe questionnaires at the individual patient level. *BMC Health Serv Res* 2015; 15: 447. [PubMed] [Full Text]
20. van Boven JF, **Kocks JWH**, et al. Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol. *NPJ Prim Care Respir Med* 2015; 25: 15051. [PubMed] [Full Text]
21. Braithwaite I, **Kocks J**, et al. Randomised controlled trial of topical kanuka honey for the treatment of rosacea. *BMJ Open* 2015; 5(6): e007651. [PubMed] [Full Text]
22. van der Leeuw S, **Kocks JW**, et al. The minimal clinically important difference of the control of allergic rhinitis and asthma test (CARAT): cross-cultural validation and relation with pollen counts. *NPJ Prim Care Respir Med* 2015; 25: 14107. [PubMed] [Full Text]
23. Metting EI, **Kocks JH**, et al. Feasibility and effectiveness of an asthma/COPD service for primary care: a cross-sectional baseline description and longitudinal results. *NPJ Prim Care Respir Med* 2015; 25: 14101. [PubMed] [Full Text]
24. Boland MRS, **Kocks JWH**, et al. Mapping the clinical chronic obstructive pulmonary disease questionnaire onto generic preference-based EQ-5D values. *Value Health* 2015; 18(2): 299-307. [PubMed] [Full Text]
25. Kruis AL, **Kocks JWH**, et al: Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. *PLoS One* 2014, 9(3): e90145. [PubMed] [Full Text]
26. **Kocks JWH**, et al. Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2013; 8: 273-86. [PubMed] [Full Text]
27. **Kocks J**, et al. Putting health status guided COPD management to the test: protocol of the MARCH study. *BMC Pulm Med* 2013; 13: 41. [PubMed] [Full Text]
28. Tsiligianni IG, **Kocks JWH**, et al. Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). *BMC Pulm Med* 2012; 12(1): 20. [PubMed] [Full Text]

29. **Kocks JWH**, et al. Health status in routine clinical practice: validity of the Clinical COPD Questionnaire at the individual patient level. *Health Qual Life Outcomes* 2010; 8(1): 135. [PubMed] [Full Text]
30. Reda AA, **Kocks JWH**, et al. Reliability and validity of the clinical COPD questionnaire and chronic respiratory questionnaire. *Respir Med* 2010; 104(11): 1675-1682. [PubMed] [Full Text]
31. **Kocks JWH**, et al. Clothing make the doctor--patients have more confidence in a smartly dressed GP. *Ned Tijdschr Geneesk* 2010; 154(51-52): A2898. [PubMed] [Full Text]
32. **Kocks JWH**, et al. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. *Respir Res* 2006; 7: 62. [PubMed] [Full Text]
33. **Kocks JWH**, Tanja TA. A girl with haematomas. *Ned Tijdschr Geneesk* 2010; 154: A215. [PubMed] [Full Text]

Reviews and Discussion

1. **Kocks JWH**, et al. Assessing patient-reported outcomes in asthma and COPD patients: which can be recommended in clinical practice? *Curr Opin Pulm Med* 2018; 24(1): 18-23. [PubMed] [Full Text]
2. van der Schans S, **Kocks JWH**, et al. Systematic review and quality appraisal of cost-effectiveness analyses of pharmacologic maintenance treatment for chronic obstructive pulmonary disease: methodological considerations and recommendations. *Pharmacoeconomics* 2017; 35(1): 43-63. [PubMed] [Full Text]
3. van der Molen T, **Kocks JWH**, et al. The use of health status questionnaires in the management of chronic obstructive pulmonary disease patients in clinical practice. *Expert Rev Respir Med* 2014; 8(4): 1-13. [PubMed] [Full Text]
4. Vanfleteren LE, **Kocks JWH**, et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? *Thorax* 2014; 69(1): 72-9. [PubMed] [Full Text]
5. van der Molen T, **Kocks J**, et al. COPD management: role of symptom assessment in routine clinical practice. *Int J Chron Obstruct Pulmon Dis* 2013; 8: 461-471. [PubMed] [Full Text]
6. **Kocks JWH**, et al. Functional status measurement in COPD: a review of available methods and their feasibility in primary care. *Prim Care Respir J* 2011; 20(3): 269-275. [PubMed] [Full Text]
7. Tsiligianni I, **Kocks J**, et al. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. *Prim Care Respir J* 2011; 20(3): 257-268. [PubMed] [Full Text]
8. van der Molen T, **Kocks J**. Evidence based guidelines in COPD management and current treatment options. *Turkish Journal of Family Medicine and Primary Care* 2008; 2(1): 40-43. [Full Text]
9. van der Molen T, **Kocks JWH**. Do health-status measures play a role in improving treatment in chronic obstructive pulmonary disease? *Expert Opin Pharmacother* 2006; 7(1): 57-61. [PubMed] [Full Text]

Editorials

1. van der Molen T, **Kocks JWH**, et al. Finding the missing millions: can a new questionnaire help to detect undiagnosed chronic obstructive pulmonary disease? *Am J Respir Crit Care Med* 2017; 195(6): 708-710. [PubMed] [Full Text]
2. van der Molen T, **Kocks JWH**. The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide? *NPJ Prim Care Respir Med* 2014; 24: 14013. [PubMed] [Full Text]

Reports

1. Kahn N, **Kocks JWH**, et al. Clinical highlights from the 2016 European Respiratory Society International Congress. *ERJ Open Res* 2017; 3(2). [PubMed] [Full Text]
2. Gaspar L, **Kocks JWH**, et al. Human cellular differences in cAMP - CREB signaling correlate with light-dependent melatonin suppression and bipolar disorder. *Eur J Neurosci* 2014; 40(1):2206-15. [PubMed] [Full Text]

Letters

1. **Kocks JWH**, et al. Responsiveness of the COPD assessment test: the minimal clinically important difference does matter. *Chest* 2012; 142(1): 267-268. [PubMed] [Full Text]
2. Tsiligianni IG, **Kocks JWH**, et al. Highlighting CCQ-CAT calculation and advantages. *COPD* 2012; 9(3): 316-7. [PubMed] [Full Text]
3. **Kocks JWH**, van der Molen T. Risk indexes for COPD exacerbations II. *Chest* 2007; 131(6): 1986-7. [PubMed] [Full Text]